01:54 PM EST, 12/18/2024 (MT Newswires) -- Polyrizon ( PLRZ ) entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a European-based GMP-certified manufacturer, to supply clinical trial material for its PL-14 allergy blocker study that is likely to begin in 2025.

The stock tripled Wednesday as intraday volume topped 129.8 million shares versus the daily average of almost 554,000.

Nukkleus ( NUKK ) shares more than quadrupled, extending Tuesday's rally, after the company acquired a controlling stake in Star 26 Capital, a majority owner of a key supplier to Israel's defense system.

Volume topped 41.2 million versus the daily average of almost 3.33 million.

Cognition Therapeutics ( CGTX ) said a phase 2 study of CT1812 for patients with Lewy body dementia met its primary endpoint of safety and tolerability.

Shares soared 62% as volume topped 264.2 million versus the daily average of 1.56 million.

Price: 3.31, Change: +2.26, Percent Change: +215.24